BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/26/2026 9:50:21 AM | Browse: 0 | Download: 0
 |
Received |
|
2026-03-30 00:55 |
|
Peer-Review Started |
|
2026-03-31 07:04 |
|
First Decision by Editorial Office Director |
|
2026-04-15 07:58 |
|
Return for Revision |
|
2026-04-15 07:58 |
|
Revised |
|
2026-05-03 03:40 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-27 02:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-27 06:19 |
|
Articles in Press |
|
2026-05-27 06:19 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-16 01:10 |
|
Publish the Manuscript Online |
|
2026-06-26 09:50 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ronald Blanco Montecino, Nehemias Guevara Rodriguez, Noemy Coreas, Daniel Mendoza-Quispe, Yassine Kilani, Syeda Ashna Fatima Kamal, Kamran Qureshi and John M Richart |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ronald Blanco Montecino, MD, Department of Internal Medicine, Saint Barnabas Hospital, CUNY School of Medicine, 4422 Third Avenue, Bronx, NY 10457, United States. ronaldmau94@gmail.com |
| Key Words |
Hepatocellular carcinoma; Tyrosine kinase inhibitors; Atezolizumab; Bevacizumab; Second-line therapy; Disease progression; Survival outcomes; Adverse events; Meta-analysis |
| Core Tip |
Atezolizumab plus bevacizumab represents the standard first-line therapy for advanced hepatocellular carcinoma; however, treatment options after disease progression remain poorly defined. Tyrosine kinase inhibitors, established prior to the immunotherapy era, are frequently used in this setting, although their effectiveness after prior immunotherapy exposure is not well characterized. Therefore, a comprehensive evaluation of their role is needed. Our meta-analysis assessed the efficacy and safety of tyrosine kinase inhibitors after progression on atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. |
| Publish Date |
2026-06-26 09:50 |
| Citation |
Blanco Montecino R, Rodriguez NG, Coreas N, Mendoza-Quispe D, Kilani Y, Kamal SAF, Qureshi K, Richart JM. Tyrosine kinase inhibitors after progression on atezolizumab-bevacizumab in advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Hepatol 2026; 18(6): 121656
|
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i6/121656.htm |
| DOI |
https://doi.org/10.4254/wjh.121656 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
